ifosfamide has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary endpoint compares and evaluates the side effect profiles of ifosfamide-treated patients in the OP/IP settings." | 1.72 | Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. ( Arredondo, A; Babiker, H; Banh, C; Boiles, AR; Elquza, E; Kraft, A; McBride, A; Notbohm, K; Ortega, A; Persky, D; Valsvik, K, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banh, C | 1 |
| Valsvik, K | 1 |
| Arredondo, A | 1 |
| Notbohm, K | 1 |
| Elquza, E | 1 |
| Babiker, H | 1 |
| Kraft, A | 1 |
| Boiles, AR | 1 |
| Persky, D | 1 |
| Ortega, A | 1 |
| McBride, A | 1 |
| Ostrowska, B | 1 |
| Domanska-Czyz, K | 1 |
| Romejko-Jarosinska, J | 1 |
| Osowiecki, M | 1 |
| Targonski, L | 1 |
| Poplawska, L | 1 |
| Konecki, R | 1 |
| Kotarska, M | 1 |
| Szymanski, M | 1 |
| Borawska, A | 1 |
| Swierkowska, M | 1 |
| Dabrowska-Iwanicka, A | 1 |
| Druzd-Sitek, A | 1 |
| Paszkiewicz-Kozik, E | 1 |
| Mroz-Zycinska, E | 1 |
| Tajer, J | 1 |
| Wojciechowska-Lampka, E | 1 |
| Osiadacz, W | 1 |
| Rymkiewicz, G | 1 |
| Lapinska, G | 1 |
| Wojewodzka-Mirocha, M | 1 |
| Michalski, W | 1 |
| Walewski, J | 1 |
2 other studies available for ifosfamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Savings; COVID-19; Etoposide; Humans; Ifosfamid | 2022 |
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; COVID-19; Cytarabi | 2023 |